Catalysts for $IGC
651 tracked
Dec 22, 2025
approval
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approval
acetaminophen ER
→
Dec 22, 2025
approval
PERCOCET (ACETAMINOPHEN) — FDA approval
IGC Pharma, Inc.
→
Dec 22, 2025
approval
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approval
IGC Pharma, Inc.
→
Dec 14, 2025
approval
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approval
acetaminophen ER
→
Dec 11, 2025
approval
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approval
IGC Pharma, Inc.
→
Dec 5, 2025
approval
ACETAMINOPHEN — FDA approval
IGC Pharma, Inc.
→
Nov 25, 2025
approval
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approval
IGC Pharma, Inc.
→
Nov 24, 2025
approval
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approval
IGC Pharma, Inc.
→
Nov 19, 2025
approval
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approval
IGC Pharma, Inc.
→
Nov 12, 2025
recall
Aero Healthcare recall (Cls II)
IGC Pharma, Inc.
→
Nov 5, 2025
recall
QuVa Pharma, Inc. recall (Cls II)
IGC Pharma, Inc.
→
Oct 2, 2025
device pma
Medinol, Ltd. — EluNIR Ridaforolimus Eluting Coronary Stent System (PMA supplement)
IGC Pharma, Inc.
→
Aug 15, 2025
device pma
Medinol, Ltd. — EluNIR Ridaforolimus Eluting Coronary Stent System (PMA supplement)
IGC Pharma, Inc.
→
Aug 7, 2025
device pma
Medinol, Ltd. — EluNIR-PERL Ridaforolimus Eluting Coronary Stent System (PMA supplement)
IGC Pharma, Inc.
→
Jul 29, 2025
approval
BUPRENORPHINE HYDROCHLORIDE — FDA approval
IGC Pharma, Inc.
→
Jul 29, 2025
approval
BUPRENORPHINE HYDROCHLORIDE — FDA approval
IGC Pharma, Inc.
→
Jul 3, 2025
device pma
Medinol, Ltd. — EluNIR Ridaforolimus Eluting Coronary Stent System (PMA supplement)
IGC Pharma, Inc.
→
May 30, 2025
device pma
Medinol, Ltd. — EluNIR Ridaforolimus Eluting Coronary Stent System (PMA supplement)
IGC Pharma, Inc.
→
Apr 14, 2025
approval
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE (ACETAMINOPHEN) — FDA approval
IGC Pharma, Inc.
→
Apr 3, 2025
approval
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approval
acetaminophen ER
→
Apr 2, 2025
recall
QuVa Pharma, Inc. recall (Cls II)
IGC Pharma, Inc.
→
Apr 2, 2025
recall
QuVa Pharma, Inc. recall (Cls II)
IGC Pharma, Inc.
→
Apr 2, 2025
recall
QuVa Pharma, Inc. recall (Cls II)
IGC Pharma, Inc.
→
Mar 13, 2025
approval
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approval
IGC Pharma, Inc.
→
Feb 21, 2025
approval
BUPRENORPHINE HYDROCHLORIDE — FDA approval
IGC Pharma, Inc.
→
Feb 21, 2025
approval
BUPRENORPHINE HYDROCHLORIDE — FDA approval
IGC Pharma, Inc.
→
Feb 21, 2025
approval
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approval
IGC Pharma, Inc.
→
Feb 21, 2025
approval
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approval
BUPRENORPHINE HYDROCHLORIDE
→
Feb 21, 2025
approval
BUPRENORPHINE HYDROCHLORIDE — FDA approval
IGC Pharma, Inc.
→
Feb 21, 2025
approval
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approval
IGC Pharma, Inc.
→